Navigation Links
Zyngenia, Inc. Promotes Chief Scientific Officer and Hires Chief Business Officer

GAITHERSBURG, Md., Dec. 12, 2011 /PRNewswire/ -- Zyngenia, Inc., a biopharmaceutical company developing the next generation of antibody-based drugs called Zybodies™, announced today that it has promoted David M. Hilbert, Ph.D., to Chief Scientific Officer and appointed Daniel L. Menichella as Chief Business Officer.

"Since our start in September 2009, Zyngenia has made tremendous progress in both developing novel multi-specific biological drugs and in validating our technology platform," said Zyngenia President and CEO Peter A. Kiener, D.Phil. "As we build on our discovery and development successes, we continue to build a world-class executive team. The promotion of David Hilbert reflects his outstanding leadership in guiding the R&D direction of our company as we create innovative multi-specific biological drugs that better treat the unmet medical need of patients.   We are also very pleased to welcome Dan Menichella to the Zyngenia team. His depth of experience in business development and corporate strategy in the global biopharmaceutical industry will greatly enhance our ability to grow Zyngenia and the portfolio of drugs that our technology will provide."

Promotion of David M. Hilbert

Dr. Hilbert is a highly successful biotechnology entrepreneur and drug developer.  He joined Zyngenia in October 2009 as Vice President, Research and Development and has been responsible for leading the R&D efforts in the development of multi-specific antibody-based therapeutics. From 2006 to 2009, Dr. Hilbert worked as a consultant with leading scientists, executives, and venture firms in assisting start-up biotechnology companies with t

SOURCE Zyngenia, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. Zyngenia, Inc. Raises $10 Million in Series A Funding
2. China Bionanometer Industries Corporation Promotes New Product Beauty Look in China
3. WuXi PharmaTech Promotes Dr. Rujian Ma to VP of Synthetic Chemistry
4. AMDL, Inc. Promotes CFO Akio Ariura to Chief Operating Officer and Expands Management Team
5. BioMed Realty Trust Promotes Kent Griffin to President
6. Genesis HealthCare Promotes Wendy LaBate To Senior Vice President of Operations for the Northeast Area
7. BioStorage Technologies, Inc. Promotes Lori Ball to Senior Vice President and Expands Role
8. Merrimack Pharmaceuticals Promotes Ulrik B. Nielsen, Ph.D. to Chief Scientific Officer and Edward J. Stewart to Senior Vice President of Business Development
9. Pathway for Biosimilars Act Protects Patients, Promotes Competition, Preserves Innovation and Creates Quality Jobs, Lilly Says
10. Ratcliff Promotes Jorge Burbano to Senior Associate; Tess Kavanagh and Tony Keung to Associate
11. Nektar Therapeutics Promotes Lorianne Masuoka, M.D. to Chief Medical Officer
Post Your Comments:
(Date:5/1/2015)... OncoTAb, Inc., a University ... announced that Pinku Mukherjee, Ph.D. has received the ... Governors’ highest faculty honor. Mukherjee received the award, which ... her innovative research and development of cancer diagnostics and ... crowning moment in my scientific career,” said Mukherjee, OncoTAb ...
(Date:5/1/2015)... , May 1, 2015 Pfenex ... engaged in the development of biosimilar therapeutics including ... today that its first quarter 2015 financial results ... before the open of market. At 8:30 am Eastern ... to discuss the financial results and provide a ...
(Date:5/1/2015)... 1, 2015 A new report ... drugs will reach $22.4bn in 2019. That revenue forecast ... and Market Prospects 2015-2025 ,  published in ... is to provide forecasts and qualitative analyses of the ... and consultancy in London, UK . ...
(Date:5/1/2015)... May 1, 2015 Albany Molecular Research Inc. ... S. Marth , AMRI,s President and Chief Executive Officer, ... 2015 Health Care Conference on Wednesday, May 13, 2015 ... webcast of the presentation can be accessed at AMRI,s ... The webcast will be archived for 90 days ...
Breaking Biology Technology:OncoTAb CSO Awarded the University of North Carolina’s O. Max Gardner Award 2Pfenex To Report First Quarter 2015 Results and Provide Business Update on Thursday, May 14, 2015 2Antithrombotic Drugs: World Industry and Market Prospects 2015-2025 2Antithrombotic Drugs: World Industry and Market Prospects 2015-2025 3Antithrombotic Drugs: World Industry and Market Prospects 2015-2025 4Antithrombotic Drugs: World Industry and Market Prospects 2015-2025 5AMRI to Present at the Bank of America Merrill Lynch 2015 Health Care Conference 2
... New Launches Should Contribute Significantly in Second Half, ... PRX ) today announced results for the,second quarter ended ... For the second quarter ended June 28, 2008, Par ... $20.1 million, or $0.60 per diluted,share. This is compared with ...
... ITMN ) today announced that Daniel G. Welch, ... Canaccord Adams 28th Annual,Global Growth Conference in Boston on ... access a live audio webcast of the presentation, investors ... relations page of InterMune,s,corporate website at . ...
... YORK, Aug. 7 Microbes, Inc. today announced that ... all of its outstanding,Class B Common Stock Purchase Warrants, ... 2 until 12:00 midnight, New York City time, on,Friday, ... at 12:00,midnight, New York City time, on August 7, ...
Cached Biology Technology:Par Pharmaceutical Reports Second Quarter 2008 Results 2Par Pharmaceutical Reports Second Quarter 2008 Results 3Par Pharmaceutical Reports Second Quarter 2008 Results 4Par Pharmaceutical Reports Second Quarter 2008 Results 5Par Pharmaceutical Reports Second Quarter 2008 Results 6Par Pharmaceutical Reports Second Quarter 2008 Results 7Par Pharmaceutical Reports Second Quarter 2008 Results 8
(Date:3/31/2015)... NEW YORK , March 31, 2015  Elephant ... the "Company"), a global provider of Software Defined Network ... solutions, today announced total revenue of approximately $20.4 million ... to a restated $19.5 million for the year ended ... of calendar 2014, the Company had completed its multi-year ...
(Date:3/30/2015)... 26, 2015 Research and Markets ( ... "Global Gesture Recognition Market in Automotive Sector 2014-2018" ... the Global Gesture Recognition market in Automotive Sector to ... 2013-2018. Gesture recognition is the ability of ... of an individual. Gesture recognition technology can be 2D-based ...
(Date:3/24/2015)... --Research and Markets ( ) has ... Market 2015-2019" report to their offering. ... grow at a CAGR of 23.5 percent over the ... scenario and the growth prospects of the Global Iris ... market size, the report considers the revenue generated from ...
Breaking Biology News(10 mins):Elephant Talk Reports 2014 Fourth Quarter and Year End Financial Results 2Elephant Talk Reports 2014 Fourth Quarter and Year End Financial Results 3Elephant Talk Reports 2014 Fourth Quarter and Year End Financial Results 4Elephant Talk Reports 2014 Fourth Quarter and Year End Financial Results 5Elephant Talk Reports 2014 Fourth Quarter and Year End Financial Results 6Global Gesture Recognition Market in Automotive Sector Report 2015 - Growing Number of Partnerships 2Global Iris Recognition Market 2015-2019 with 3M Cogent, Bioenable Technologies, Cross Match Technology, Iris ID Systems & Safran Dominating 2
... a key source of water for millions of people in ... climate changes as expected and future water usage is not ... of Oceanography, UC San Diego. Without Lake ... no buffer to sustain the population of the Southwest through ...
... Feb. 11 Most fashion consumers consider,custom-made jeans ... lottery,winners. But Intellifit, a leader in proprietary apparel ... perception., This week, the company will begin ... company retail store outside of Philadelphia. Using Intellifit,technology, ...
... the Moores Cancer Center at University of California, San Diego ... were treated with a gene therapy protocol began making antibodies ... be published on line the week of February 11-15 in ... of Science. Researchers led by Thomas J. Kipps, M.D., ...
Cached Biology News:Lake Mead could be dry by 2021 2Lake Mead could be dry by 2021 3Intellifit(R) Offers Custom-Made Jeans with a High-Tech Twist 2Gene therapy protocol at UCSD activates immune system in patients with leukemia 2